权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of anti-angiogenesis therapy targeting integrin

针对整合素的抗血管生成疗法的开发

基本信息

批准号：
9023506
负责人：
Zhi-Ren Liu
金额：
$ 39.38万
依托单位：
GEORGIA STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-01 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9023506
关键词：
Adverse effects Affect Affinity Angiogenesis Inhibition Angiogenesis Inhibitors Animal Cancer Model Animal Model Anoikis Antibodies Antineoplastic Agents Apoptosis Avastin Binding Biodistribution Biological Biological Models Blocking Antibodies Blood Circulation Blood Vessels Breast Cancer Cell Breast Cancer cell line Caliber Cancer Model Cancer Patient Caspase Cell Line Cells Characteristics Chemicals Cilengitide Clinical Clinical Research Complex Computer Simulation Development Docking Dose Drug Kinetics ERBB2 gene Effectiveness Endostatins Endothelial Cells Exhibits FDA approved Fluorouracil Focal Adhesions Future Goals Health Human Immune Immunologics Implant In Vitro Induction of Apoptosis Integrins Interferons KDR gene Knockout Mice Laboratories Lead Ligand Binding Ligands MDA MB 435 Malignant Neoplasms Mammary gland Modeling Molecular Mono-S Mus Mutation Neoplasm Metastasis Normal tissue morphology Nude Mice Ocular Melanoma Organ PC3 cell line Paclitaxel Pathway interactions Pharmaceutical Preparations Play Procedures Protein Engineering Protein Structure Initiative Proteins Rat-1 Rattus Research Project Grants Role Signal Transduction Site Solid Neoplasm Testing Therapeutic Agents Time Tissues Toxic effect Tumor Angiogenesis Tumor-Derived Vascular Endothelial Growth Factors Vascular blood supply Work Xenograft procedure angiogenesis antiangiogenesis therapy bevacizumab cancer therapy chemotherapy clinical application crosslink design dosage in vitro activity mimetics mutant novel pre-clinical protein distribution research study success targeted agent therapeutic angiogenesis therapeutic target tumor tumor growth

项目摘要

DESCRIPTION (provided by applicant): Solid tumors will not grow beyond 3 - 4 mm in diameter without building up their own blood supply. Due to the essential role of tumor angiogenesis, anti-angiogenesis, mono-therapy or in- combination with other therapeutic agents, represents a very promising approach for cancer treatments. Great successes have been achieved, such as Avastin, a FDA approved anti- angiogenesis drug. However, clinical studies revealed that the cancer patient survival benefits of antiangiogenic drugs have thus far been insignificant. In addition, most current studies in development of anti-angiogenesis agent have been mainly focused on strategies of blocking VEGF/VEGFR signaling. Many agents that are developed against the VEGF/VEGFR pathway often cause unwanted biologic side effects. There is urgent need to develop anti-angiogenesis agents by targeting many other biological pathways that are involved in both stimulation and inhibition of cancer angiogenesis. We have developed a new class of anti-angiogenesis proteins by integrin ¿v¿3 at a novel site, the large pocket formed by the I-domain of ¿v and the PSI domain of ¿3. Computational modeling demonstrated that the domain 1 of rat CD2 and human CD2 spatially fit into the designed site very well. Mutations introduced at the D1-CD2 to bridge several key contacts between designed protein and the integrins optimize the binding of the designed protein with integrin. The designed proteins exhibit strong in vitro activity in induction of apoptosis on endothelial HUVEC cells with no effects on other cells. Tests with tumor nude mice PC-3 xenografts show that the designed proteins strongly inhibit tumor growth. Parallel analyses suggested that our developed protein anti-angiogenesis agents are significantly more effective than Avastin in inhibiting tumor growth. In this proposed research project, we propose experiments to further verify whether the designed protein indeed interact with integrin at the designed site, and whether the designed protein indeed exert its activity by targeting the integrin. We will extensively test the effectiveness of the developed protein anti-angiogenesis agents by various animal models of human cancers. We also design experiments to test whether our developed anti-angiogenesis proteins will have great potency for cancer treatment in combination with other anti-cancer drugs. To facilitate potential future clinical applications, we propose experiments to extensively characterize toxicity and bio-distribution of the protein agents. Our study will lead to development of a new and more effective anti-angigenesis agent for cancer treatment.

描述（由申请人提供）：实体瘤在不建立自身血液供应的情况下，直径不会超过3 - 4 mm。由于肿瘤血管生成的重要作用，抗血管生成、单一治疗或与其他治疗剂组合代表了非常有前途的癌症治疗方法。如FDA批准的抗血管生成药物阿瓦斯丁（Avastin），已取得了巨大的成功.然而，临床研究表明，迄今为止，抗血管生成药物对癌症患者生存的益处并不显着。此外，目前开发抗血管生成剂的大多数研究主要集中在阻断VEGF/VEGFR信号转导的策略上。针对VEGF/VEGFR通路开发的许多药物通常会引起不必要的生物副作用。目前迫切需要通过靶向参与刺激和抑制癌症血管生成的许多其他生物学途径来开发抗血管生成剂。我们通过整合素<$v <$3在一个新的位点开发了一类新的抗血管生成蛋白，该位点是由<$v的I结构域和<$3的PSI结构域形成的大口袋。计算模型表明，大鼠CD 2和人CD 2的结构域1在空间上非常适合设计的位点。在D1-CD 2处引入突变以桥接设计的蛋白质和整联蛋白之间的几个关键接触，从而优化设计的蛋白质与整联蛋白的结合。所设计的蛋白在体外诱导内皮HUVEC细胞凋亡方面表现出很强的活性，而对其他细胞没有影响。用肿瘤裸鼠PC-3异种移植物进行的测试表明，所设计的蛋白质强烈抑制肿瘤生长。平行分析表明，我们开发的蛋白质抗血管生成剂在抑制肿瘤生长方面明显比阿瓦斯丁更有效。在这个拟议的研究项目中，我们提出了实验，以进一步验证设计的蛋白质是否确实与整合素在设计的网站上相互作用，以及设计的蛋白质是否确实发挥其活性，通过靶向整合素。我们将通过各种人类癌症动物模型广泛测试所开发的蛋白质抗血管生成剂的有效性。我们还设计了实验来测试我们开发的抗血管生成蛋白质是否与其他抗癌药物联合治疗癌症。为了促进未来潜在的临床应用，我们提出了实验，以广泛表征蛋白质药物的毒性和生物分布。我们的研究将导致开发一种新的和更有效的抗血管生成剂用于癌症治疗。